10-K: Lantheus Navigates Strategic Shifts, Pipeline Progress in 2025

Lantheus Holdings, Inc. reports strategic divestitures, key acquisitions, and pipeline advancements in 2025, alongside leadership changes and PYLARIFY revenue adjustments.

Summary

• Lantheus completed the sale of its SPECT business to SHINE Technologies, LLC on January 1, 2026, for total consideration of up to $155.0 million, to focus on PET radiodiagnostics and microbubbles.
• Acquired Life Molecular Imaging Limited (LMI) on July 21, 2025, for an upfront cash payment of $352.9 million, with potential additional earn-out and milestone payments of up to $400.0 million, adding Neuraceq and RM2 assets.
• Acquired Evergreen Theragnostics, Inc. on April 1, 2025, for an upfront cash payment of $276.4 million, with potential additional milestone payments of up to $727.5 million, enhancing CDMO services and adding LNTH-2501.
• Mary Anne Heino was appointed Executive Chair on November 7, 2025, and CEO on January 1, 2026, following Brian Markison's retirement on December 31, 2025.
• The FDA accepted the New Drug Application (NDA) for a new formulation of the F-18 PSMA PET imaging agent (PYLARIFY) with a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2026.
• The FDA accepted the NDA for MK-6240, a tau-targeted PET imaging agent for Alzheimer's disease, with a PDUFA target action date of August 13, 2026, after it met co-primary endpoints in two pivotal studies.
• The FDA set a PDUFA target action date of March 29, 2026, for LNTH-2501, a diagnostic kit for neuroendocrine tumors.
• An exclusive licensing agreement was signed with GE Healthcare on September 24, 2025, for the development, manufacture, and commercialization of piflufolastat F-18 (PYLARIFY) in Japan.
• PYLARIFY's Transitional Pass-Through (TPT) Status expired on December 31, 2024, leading to a shift from Average Sales Price (ASP)-based payment to a lower Mean Unit Cost (MUC)-based payment in the hospital outpatient setting.
• Net income decreased by $78.883 million (25.2%) to $233.559 million in 2025 from $312.442 million in 2024.
• Total revenues increased slightly by $7.699 million (0.5%) to $1,541.609 million in 2025 from $1,533.910 million in 2024.
• PYLARIFY revenue decreased by $68.718 million (6.5%) to $989.116 million in 2025, primarily due to a decrease in net sales price.
• DEFINITY revenue increased by $12.456 million (3.9%) to $330.248 million in 2025 due to increased sales volume.
• Neuraceq generated $51.447 million in revenue in 2025 following the LMI acquisition.
• Research and development (R&D) expenses increased by $9.210 million (5.5%) to $177.308 million in 2025, driven by acquisition-related payments and project costs.
• General and administrative expenses increased by $81.432 million (42.0%) to $275.121 million in 2025, primarily due to acquisitions and litigation expenses.
• The Phase 3 SPLASH study for PNT2002 was confounded by patient crossover, leading to no current plans to pursue an NDA or further invest in this asset.
• PNT2003's Abbreviated New Drug Application (ANDA) was accepted by the FDA but is subject to patent infringement litigation by Novartis, potentially delaying approval by up to 30 months.
• The company repurchased 3.5 million shares for approximately $200.0 million under the 2025 Program, with approximately $200.0 million remaining available for repurchase.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but leaning negative report. While strategic acquisitions and pipeline advancements show long-term potential, the significant decline in net income, PYLARIFY revenue decrease due to reimbursement changes, and ongoing litigation for a key pipeline asset (PNT2003) present immediate headwinds and uncertainties.

Positives

• Strategic focus sharpened by the divestiture of the SPECT business, allowing for greater concentration on PET radiodiagnostics and microbubbles.
• Successful acquisition of Life Molecular Imaging Limited, expanding the Alzheimer's disease radiodiagnostic commercial infrastructure and international footprint with Neuraceq and RM2 assets.
• Acquisition of Evergreen Theragnostics, Inc. enhances CDMO services and adds LNTH-2501 to the pipeline.
• New formulation of F-18 PSMA PET imaging agent (PYLARIFY) NDA accepted by FDA with a PDUFA target action date of March 6, 2026, designed to enhance product stability and increase batch production.
• MK-6240 (tau-targeted PET imaging agent for Alzheimer's) NDA accepted by FDA with a PDUFA target action date of August 13, 2026, following successful achievement of co-primary endpoints in two pivotal studies.
• LNTH-2501 (diagnostic kit for neuroendocrine tumors) NDA accepted by FDA with a PDUFA target action date of March 29, 2026.
• DEFINITY sales volume increased by 3.9% in 2025, and FDA approval was received for its use in pediatric patients in March 2024.
• Exclusive licensing agreement with GE Healthcare for piflufolastat F-18 (PYLARIFY) in Japan generates upfront fees, development milestones, and tiered royalties.
• CMS maintained separate payment for PYLARIFY after TPT Status expiration, albeit at a lower MUC rate, ensuring continued reimbursement.
• LNTH-2403 received Orphan Drug and Rare Pediatric Disease designation from the FDA for osteosarcoma.
• LNTH-2515 (florbetaben F-18 injection) received Fast Track designation from the FDA for the diagnosis of amyloid light chain and transthyretin cardiac amyloidosis.
• Strong intellectual property portfolio with patents for PYLARIFY and DEFINITY extending to 2037.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Net income decreased by 25.2% in 2025 compared to 2024, from $312.442 million to $233.559 million.
• PYLARIFY revenue decreased by 6.5% in 2025, primarily due to a decrease in net sales price.
• Expiration of PYLARIFY's TPT Status on December 31, 2024, resulted in lower MUC-based reimbursement, creating a financial incentive for customers to use competitive products that still have TPT Status.
• Neuraceq's MUC payment rate is lower than competitors, potentially impacting its adoption and revenue growth.
• Development of PNT2002 was discontinued due to confounded Phase 3 SPLASH study results, representing a failed pipeline asset.
• PNT2003 is subject to patent infringement litigation by Novartis, which could delay FDA approval by up to 30 months.
• Increased competition for PYLARIFY is expected from existing and potential generic entrants after its New Chemical Entity (NCE) exclusivity expires in May 2026.
• Potential for generic DEFINITY challengers exists, as its Orange Book-listed composition of matter patent expired in June 2019, and a CREATES Act request for samples has been received.
• General and administrative expenses increased significantly by 42.0% in 2025, partly due to acquisition-related and litigation expenses.
• Net cash provided by operating activities decreased to $390.141 million in 2025 from $544.750 million in 2024.
• Net cash used in investing activities increased significantly to $627.168 million in 2025 from $226.015 million in 2024, primarily due to acquisitions.
• Stock price experienced significant volatility in 2025, with a high of $110.01 and a low of $50.11.
• Leadership transition with the former CEO retiring and an interim CEO appointed can be disruptive and create uncertainty.

Risks

• Continued substantial revenue contribution from PYLARIFY is dependent on PMF manufacturing capacity, adequate coding/coverage/payment (impacted by TPT Status expiration and lower MUC rates), ability to differentiate from competitors, and potential generic entry after NCE exclusivity expires in May 2026.
• Ability to grow DEFINITY use faces competition from other ultrasound enhancing agents and potential generic competitors due to patent and regulatory exclusivity expirations.
• Neuraceq growth depends on expanding geographical access, increasing manufacturing capacity, increased adoption of beta-amyloid PET and anti-amyloid therapeutics, and ability to differentiate from competitors despite MUC payment rate disparity.
• Dependence on third-party manufacturers and suppliers for PYLARIFY, Neuraceq, and DEFINITY, and sole suppliers for certain components, poses risks of supply chain disruptions, delays, and inability to meet demand.
• Highly competitive markets for all products, with larger, more diversified competitors potentially offering price reductions, portfolio bundling, or superior new products.
• Dependence on third-party payors (Medicare, Medicaid, private) for adequate coverage and reimbursement, with reductions in rates, changes in healthcare reform (e.g., IRA's drug negotiation, OBBBA's Medicaid cuts), and regulatory changes potentially adversely affecting business.
• Recent turnover in leadership and senior management team, including interim CEO appointment, could disrupt business, hinder strategic planning, and negatively impact operations.
• Use of radiopharmaceutical diagnostic products depends on the availability of staff at imaging centers/hospitals and PET scanners; shortages or capacity constraints could impact revenue.
• Inability to effectively manage existing products, successfully develop/launch new products/indications, or adapt to rapid technological/medical practice changes.
• Adverse effects from prevailing economic conditions, financial instability of customers, inflationary pressures, and tariffs.
• Interruption in ability to fulfill CDMO or research program supply obligations could harm reputation and business.
• Risks associated with integrating acquired businesses (Life Molecular, Evergreen) and supporting transitional services for divested businesses (SPECT), including unforeseen expenses, integration challenges, and failure to realize anticipated benefits.
• Risk of third-party intellectual property infringement claims (e.g., PNT2003 litigation), inability to protect IP, challenges to patent validity/enforceability, and trade secret disclosure.
• The PNT2003 patent infringement lawsuit by Novartis could delay FDA approval by up to 30 months.
• Dependence on third-party licenses for product rights, with risks of failing to meet milestones or disagreements leading to loss of rights.
• Outstanding convertible senior notes and revolving credit facility may limit financial flexibility, increase interest expense, and make additional financing difficult.
• Stock price fluctuations due to various factors, including financial results, analyst reports, competition, and litigation.
• Ongoing securities class action and shareholder derivative lawsuits could incur substantial costs and divert management attention.
• Risks from unauthorized access, security breaches, and system disruptions to information technology infrastructure.
• Risks that AI-generated content/analyses could be deficient, or competitors may adopt AI more effectively, exacerbating other risks.
• Compliance with environmental laws, handling hazardous/radioactive materials, and decommissioning costs.

Future Outlook

Lantheus plans to ensure a smooth rollout of the new PYLARIFY formulation, if approved, including seeking three years of TPT Status and continuing to advocate for ASP-based payment from CMS. The company expects to increase DEFINITY usage through physician education and aims for Neuraceq growth via expanded geographical access, increased manufacturing, and clinical differentiation. Lantheus will continue to seek strategic partnerships and acquisitions in oncology, neurology, and other areas to advance its pipeline. The company is monitoring the impact of the Inflation Reduction Act and plans a strategic program in 2026 to streamline operations, focusing on radiodiagnostics and exploring value-maximizing alternatives for radiotherapeutic assets. Management believes current liquidity will be sufficient for future cash requirements.

Management Comments

• Management believes that our diagnostic products provide information that enables HCPs to better detect and characterize, or rule out, disease, with the potential to achieve better patient outcomes, reduce patient risk, and limit overall costs.
• Management believes that the new PYLARIFY formulation was designed to enhance product stability and increase batch production, with the potential to enhance supply flexibility and improve operating leverage across the network.
• Management believes MUC (Mean Unit Cost) is a less accurate reflection of actual purchasing costs of the hospital than ASP (Average Sales Price) is.
• Management believes that both MK-6240 and LNTH-2620, as tau imaging agents, and NAV-4694, as a beta amyloid imaging agent, have the potential to expand our Neurology franchise.
• Management believes that its cybersecurity program is designed to effectively mitigate the risks of material cybersecurity incidents.
• Management does not expect that its cybersecurity program will prevent or detect all occurrences of cybersecurity incidents, material or otherwise.
• Management believes that its operations currently comply in all material respects with applicable environmental laws and regulations.
• Management generally believes that it will be able to offset some of the effect of price-level changes by adjusting our product prices and implementing operating efficiencies.

Industry Context

StockSavvy.ai notes that Lantheus is strategically repositioning itself within the radiopharmaceutical industry, divesting its SPECT business to sharpen its focus on the higher-growth PET radiodiagnostics and microbubbles segments. This aligns with a broader industry trend of specialization and investment in advanced diagnostic and therapeutic modalities. The acquisitions of Life Molecular Imaging and Evergreen Theragnostics reflect a push into Alzheimer's diagnostics and radiopharmaceutical CDMO services, diversifying its pipeline and capabilities in competitive markets dominated by larger players like Novartis, Lilly, and GE Healthcare. The challenges with PYLARIFY's reimbursement status and the PNT2003 litigation highlight the significant regulatory and intellectual property hurdles inherent in the pharmaceutical sector.

Comparison to Industry Standards

• PYLARIFY competes with three Gallium-68-based PSMA imaging agents (from Telix Pharmaceuticals Limited, Blue Earth Diagnostics Ltd., and Novartis AG) and an F-18 PSMA PET imaging agent (from Blue Earth Diagnostics Ltd.), as well as other non-PSMA PET imaging agents.
• DEFINITY holds over 80% share of the U.S. segment for ultrasound enhancing agents in echocardiography procedures, competing with GE HealthCare Limited's Optison and Bracco Diagnostics Inc.'s Lumason.
• Neuraceq competes with two commercially available F-18 beta-amyloid-targeting PET imaging agents from Eli Lilly and Co and GE Healthcare.
• The MUC payment rate for Neuraceq is lower than that of competitive products from Eli Lilly and Co and GE Healthcare, potentially impacting its market position.
• Other competitive PSMA PET imaging agents continue to have TPT Status after December 31, 2024, providing a financial incentive for customers to use them over PYLARIFY, which lost its TPT Status.
• For PNT2003, principal competitors may include Novartis AG, ITM Radiopharma, Curium, and RayzeBio (acquired by Bristol Myers Squibb).
• For MK-6240 and NAV-4694, principal competitors may include Lilly and GE Healthcare.
• For LNTH-2501, principal competitors may include Curium and Novartis AG.

Management Changes

Corporate Governance

Legal Proceedings

• **PNT2003 Patent Infringement Litigation**: On January 26, 2024, the company was sued in the U.S. District Court for the District of Delaware by Advanced Accelerator Applications USA, Inc. and Advanced Accelerator Applications SA (Novartis entities) for patent infringement in response to the filing of its Abbreviated New Drug Application (ANDA) for PNT2003. A trial was conducted in December 2025, and the company is currently awaiting the court's decision. This litigation could subject FDA approval to a stay of up to 30 months.
• **Healthcare-related Imaging Software Developer Patent Infringement Lawsuit**: On February 23, 2024, the company filed a patent infringement lawsuit against a healthcare-related imaging software developer. The court dismissed the developer's motion to dismiss as to invalidity but granted it as to certain allegations of infringement. This litigation is ongoing.
• **Securities Class Action**: On September 9, 2025, a putative securities class action (Margolis v. Lantheus Holdings, Inc., et al.) was initiated in the U.S. District Court for the Southern District of New York, alleging materially false or misleading statements or omissions in violation of the Exchange Act. This action has been consolidated with a related action (Indiana Pub. Ret. Sys. v. Lantheus Holdings, Inc., et al.), and the lead plaintiff may file an amended complaint by March 13, 2026.
• **Shareholder Derivative Action**: On December 17, 2025, a shareholder derivative action (Lelchuk v. Heino et al.) was filed in the U.S. District Court for the Southern District of New York, nominally on behalf of the company, naming current directors and officers as defendants. The complaint largely repeats the allegations from the consolidated securities class action and asserts claims for alleged breaches of fiduciary duties, aiding and abetting breach of fiduciary duty, unjust enrichment, waste of corporate assets, and violations of the Exchange Act.

Stakeholder Impact

• **Shareholders**: Potential for stock price volatility due to financial performance, ongoing litigation, and competitive pressures. The share repurchase program aims to return value, but dilution risk exists from convertible notes if settled in stock. Anti-takeover provisions may limit acquisition premiums.
• **Employees**: Leadership changes, organizational restructuring (approximately 75 employees transitioned out in 2024), and a sharpened business focus could impact job security and morale. The company emphasizes competitive compensation, benefits, and an inclusive, ethical culture.
• **Customers**: Changes in reimbursement policies (e.g., PYLARIFY TPT status expiration, Neuraceq MUC rates) could affect product affordability and access. New product launches (new PYLARIFY formulation, MK-6240, LNTH-2501) aim to offer improved diagnostics and patient outcomes.
• **Suppliers**: Dependence on sole or limited suppliers for raw materials and manufacturing creates supply chain risks, potentially impacting product availability and costs.
• **Creditors**: The company's outstanding convertible notes and revolving credit facility include covenants that limit financial flexibility, and interest rate fluctuations could increase debt service costs.

Next Steps

• Complete a comprehensive search process to identify and appoint the Company's next CEO.
• Work closely with clinicians and PMF sites to ensure a smooth rollout of the new PYLARIFY formulation, if approved.
• Apply for CMS reimbursement for the new PYLARIFY formulation, including seeking three years of TPT Status.
• Continue working with CMS on the potential adoption of payment based on ASP rather than MUC for diagnostic radiopharmaceuticals.
• Continue to prosecute and maintain patents and patent applications in connection with DEFINITY.
• Continue to seek qualification for additional PMFs in 2026 for PYLARIFY and Neuraceq.
• Continue to educate physicians and healthcare professionals about the benefits of ultrasound enhancing agents in suboptimal echocardiograms for DEFINITY.
• Engage existing PYLARIFY customers to introduce Neuraceq and expand its geographical access by increasing manufacturing capacity.
• Educate customers on the approved uses of Neuraceq, including its ability to quantify the degree of amyloid burden in the brain.
• Identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology, and other strategic areas.
• Await the court's decision on the PNT2003 patent infringement litigation.
• The lead plaintiff may file an amended complaint in the consolidated securities class action by March 13, 2026.
• Initiate a Phase 1/2 clinical trial for LNTH-2403 in patients with relapsed/refractory osteosarcoma.
• Initiate a Phase 1b/2 clinical trial with the LNTH-2401/LNTH-2402 theranostic pair in prostate cancer patients (IND applications submitted in Q4 2025).
• Implement a strategic program in 2026 to simplify and streamline operations, focusing mainly on the radiodiagnostic business and pursuing value-maximizing alternatives for radiotherapeutic assets.

Key Dates

Recommendation

StockSavvy.ai recommends a 'Hold' position. While Lantheus is actively pursuing strategic growth through acquisitions and has a promising pipeline with several NDAs accepted, the significant decline in net income, the revenue decrease for its flagship product PYLARIFY due to reimbursement changes, and the ongoing patent litigation for PNT2003 introduce considerable uncertainty and downside risk. The discontinuation of PNT2002 also represents a setback. Investors should monitor the outcomes of the PDUFA dates, the PNT2003 litigation, and the effectiveness of the new PYLARIFY formulation's commercialization and reimbursement efforts before considering further investment. The company's strategic focus and pipeline potential are positive long-term indicators, but current headwinds warrant caution.

Keywords

Radiopharmaceuticals, Oncology, Neurology, Prostate Cancer, Alzheimer's Disease, PET Imaging, PYLARIFY, DEFINITY, Neuraceq, MK-6240, LNTH-2501, CDMO, Acquisitions, Divestitures, FDA Approval, Clinical Trials, Intellectual Property, SEC Filing, 10-K, Lantheus Holdings